Eli Lilly’s experimental obesity drug retatrutide achieved 28.3% average weight loss over 80 weeks, boosting regulatory approval prospects.
Eli Lilly’s retatrutide, an experimental obesity treatment, demonstrated a 28.3% average weight loss in a Phase 3 trial over 80 weeks. The weekly injection targets three hormones, outperforming existing drugs like Wegovy and Zepbound, which act on fewer pathways.
More than 45% of participants lost at least 30% of their body weight, results analysts compared to bariatric surgery outcomes. Earlier safety concerns, including abnormal skin sensations, appeared reduced in the latest trial, though gastrointestinal side effects persisted.
Lilly’s shares rose following the data release, reflecting investor optimism about retatrutide’s market potential. The company is now closer to seeking regulatory approval for the drug.